Login to Your Account


DUBLIN – After a protracted period of fiery debate, several lawsuits and no end of bureaucratic convolutions, the EMA finally made good on its promise of four years ago, to make clinical data openly and proactively available.

LONDON – With pressure on drug pricing on the rise, Jim Greenwood, president of the U.S. Biotechnology Innovation Organization was defending the industry's position in the U.K. yesterday, attending the Oxford University Union to debate the motion, "Big pharma prioritizes profit over patients."

LONDON – The EMA has followed the FDA's lead and recommended conditional approval of Abbvie Inc.'s Venclexta (venetoclax) for treating chronic lymphocytic leukemia (CLL), on the basis of a single-arm pivotal phase II study.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: